Open-Label Adalimumab for Ulcerative Colitis Patients
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Open-Label Adalimumab for Ulcerative Colitis Patients is a clinical trial[1].
Key Facts
- Open-Label Adalimumab for Ulcerative Colitis Patients is in the country of United States[2].
- Open-Label Adalimumab for Ulcerative Colitis Patients's instance of is recorded as clinical trial[3].
- Open-Label Adalimumab for Ulcerative Colitis Patients's start time is recorded as +2006-10-31T00:00:00Z[4].
- Open-Label Adalimumab for Ulcerative Colitis Patients's end time is recorded as +2008-04-30T00:00:00Z[5].
- Open-Label Adalimumab for Ulcerative Colitis Patients's sponsor is recorded as Mayo Clinic[6].
- Open-Label Adalimumab for Ulcerative Colitis Patients's main subject is recorded as colitis[7].
- Open-Label Adalimumab for Ulcerative Colitis Patients's number of participants is recorded as {'unit': '1', 'amount': '+20'}[8].
- Open-Label Adalimumab for Ulcerative Colitis Patients's title is recorded as An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients[9].
- Open-Label Adalimumab for Ulcerative Colitis Patients's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
- Open-Label Adalimumab for Ulcerative Colitis Patients's ClinicalTrials.gov ID is recorded as NCT00421642[11].
- Open-Label Adalimumab for Ulcerative Colitis Patients's research intervention is recorded as adalimumab[12].
- Open-Label Adalimumab for Ulcerative Colitis Patients's clinical trial phase is recorded as phase I clinical trial[13].
- Open-Label Adalimumab for Ulcerative Colitis Patients's research site is recorded as Mayo Clinic[14].
- Open-Label Adalimumab for Ulcerative Colitis Patients's research site is recorded as University of Chicago[15].
- Open-Label Adalimumab for Ulcerative Colitis Patients's research subject recruitment status is recorded as completed[16].
- Open-Label Adalimumab for Ulcerative Colitis Patients's research subject recruitment status is recorded as completed[17].
- Open-Label Adalimumab for Ulcerative Colitis Patients's study type is recorded as interventional study[18].